Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients

Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.

Approved check mark
Takeda's Livtencity was approved by FDA for CMV in transplant patients

Takeda Pharmaceutical Co. Ltd.'s Livtencity (maribavir) will be available in the coming days for patients with a common and serious post-transplant infection, cytomegalovirus, that is refractory to treatment.

Cleared by the US Food and Drug Administration on 23 November, the antiviral is approved for adults and pediatric patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip